Case Studies: Forced Re-branding in pharmaceuticals due to unfortunate connotations
Tata Motor force to change the brand name Zica. The Indian carmaker Tata Motors has decided to change the name of its... Read More
‘Red line’ guide on antibiotic overprescription in India
The government of India will change the packaging on certain classes of drugs to crack down on the overprescription of antibiotics. India... Read More
ViiV Healthcare acquires late-stage HIV R&D assets from BMS
GlaxoSmithKline plc, one of the world’s leading research-based pharmaceutical and healthcare companies, announced that ViiV Healthcare, the global specialist HIV company majority... Read More
What is Humanitarian Device Exemption?
Posted on25 Feb 2016
Comments0
In Humanitarian Use Device (HUD) is a device that is intended to benefit patients by treating or diagnosing a disease or condition... Read More
Vericel Announces FDA Approval of Epicel HDE Supplement
Posted on25 Feb 2016
Comments0
Vericel Corporation, a leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced that the... Read More
Humira, (adalimumab), Abbvie – 2016 Biggest Patent Expiry and Biosimilar entry
Rheumatoid arthritis treatment Humira has long been a crucial source of revenue for AbbVie: the world’s biggest-selling drug accounted for 63% of... Read More
Lupin to divest two Gavis drugs for deal approval
India’s Lupin Ltd will divest two generic drugs sold by Gavis Pharmaceuticals LLC to clear antitrust hurdles related to its $880 million... Read More
European marketing approval of AstraZeneca’s Brilique
Posted on21 Feb 2016
TagsAstraZeneca, Brilique, European marketing approval of AstraZeneca's Brilique, PEGASUS TIMI-54 study
Comments0
AstraZeneca, a global, innovation-driven biopharmaceutical business, announced that the European Commission has granted marketing authorisation for Brilique (ticagrelor) at a new 60mg... Read More
Helsinn, Mundipharma strategic deal for anamorelin
About the deal: Helsinn, the Swiss pharmaceutical Group focused on building quality cancer care, have entered into distribution, license and supply agreements... Read More
Learning from Remsima, A Remicade biosimilar
Posted on16 Feb 2016
TagsA Remicade biosimilar, biocon's biosimilar, Biosimilar, highly similar drugs, Neupogen, Remicade biosimilar, Remsima, Zarxio
Comments0
USFDA staff recently decided that Celltrion and Pfizer’s biosimilar (Remsima) to Johnson & Johnson’s Remicade for rheumatoid arthritis was “highly similar” to... Read More